Platelet and Red Blood Cell Utilization and Transfusion Independence in Umbilical Cord Blood and Allogeneic Peripheral Blood Hematopoietic Cell Transplants

Melhem Solh, Claudio G. Brunstein, Shanna Morgan, Daniel J. Weisdorf

Biology of Blood and Marrow Transplantation · 2010 · 43 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

Allogeneic hematopoietic cell transplantation (HCT) recipients have substantial transfusion requirements. Factors associated with increased transfusions and the extent of blood product use in umbilical cord blood (UCB) recipients are uncertain. We reviewed blood product use in 229 consecutive adult recipients of allogeneic HCT at the University of Minnesota: 147 with leukemia, 82 lymphoma or myeloma; 58% received unrelated UCB and 43% sibling donor peripheral blood stem cell (PBSC) grafts. Although neutrophil recovery was prompt (UCB median 17, range: 2-45 days, and PBSC 14, range: 3-34 days), only 135 of 229 (59% cumulative incidence) achieved red blood cell (RBC) independence and 157 (69%) achieved platelet independence by 6 months. Time to platelet independence was prolonged in UCB recipients (median UCB 41 versus PBSC 14 days) and in patients who had received a prior transplant (median 48 versus 32 days). Patients who received UCB grafts required more RBC through day 60 post-HCT (mean UCB 7.8 (95% confidence interval [CI] 6.7-8.9) versus PBSC 5.2 (3.7-6.7) transfusions, P = .04), and more platelet transfusions (mean 25.2 (95% CI 22.1-28.2) versus 12.9 (9.4-16.4), P < .01) compared to PBSC recipients. Patients receiving myeloablative (MA) conditioning required more RBC and platelet transfusions during the first 2 months post-HCT compared to reduced-intensity conditioning (RIC) (7.4 versus 6.2, P = .30 for RBC; 23.2 versus 17.5, P = .07 for platelets). Despite prompt neutrophil engraftment, UCB recipients had delayed platelet recovery as well as more prolonged and costly blood product requirements. Enhanced approaches to accelerate multilineage engraftment could limit the transfusion-associated morbidity and costs accompanying UCB allotransplantation. Allogeneic hematopoietic cell transplantation (HCT) recipients have substantial transfusion requirements. Factors associated with increased transfusions and the extent of blood product use in umbilical cord blood (UCB) recipients are uncertain. We reviewed blood product use in 229 consecutive adult recipients of allogeneic HCT at the University of Minnesota: 147 with leukemia, 82 lymphoma or myeloma; 58% received unrelated UCB and 43% sibling donor peripheral blood stem cell (PBSC) grafts. Although neutrophil recovery was prompt (UCB median 17, range: 2-45 days, and PBSC 14, range: 3-34 days), only 135 of 229 (59% cumulative incidence) achieved red blood cell (RBC) independence and 157 (69%) achieved platelet independence by 6 months. Time to platelet independence was prolonged in UCB recipients (median UCB 41 versus PBSC 14 days) and in patients who had received a prior transplant (median 48 versus 32 days). Patients who received UCB grafts required more RBC through day 60 post-HCT (mean UCB 7.8 (95% confidence interval [CI] 6.7-8.9) versus PBSC 5.2 (3.7-6.7) transfusions, P = .04), and more platelet transfusions (mean 25.2 (95% CI 22.1-28.2) versus 12.9 (9.4-16.4), P < .01) compared to PBSC recipients. Patients receiving myeloablative (MA) conditioning required more RBC and platelet transfusions during the first 2 months post-HCT compared to reduced-intensity conditioning (RIC) (7.4 versus 6.2, P = .30 for RBC; 23.2 versus 17.5, P = .07 for platelets). Despite prompt neutrophil engraftment, UCB recipients had delayed platelet recovery as well as more prolonged and costly blood product requirements. Enhanced approaches to accelerate multilineage engraftment could limit the transfusion-associated morbidity and costs accompanying UCB allotransplantation. IntroductionOver the past decade, there has been an increase in the use of allogeneic hematopoietic stem cell transplants (HCT) to treat hematologic malignancies and life-threatening nonmalignant hematologic disorders. This increase is attributable to newer techniques, safer preparative regimens, and expanded use of peripheral blood stems cells (PBSC) and umbilical cord blood (UCB) as graft sources [1Hiemenz J.W. Management of infections complicating allogeneic hematopoietic stem cell transplantation.Semin Hematol. 2009; 46: 289-312Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar]. Even using newer, less intensive regimens, patients undergoing HCT will receive frequent blood products as part of their supportive therapy [2Osterwalder B. Gratwohl A. Reusser P. Tichelli A. Speck B. Hematological support in patients undergoing allogenetic bone marrow transplantation.Recent Results Cancer Res. 1988; 108: 44-52Crossref PubMed Scopus (7) Google Scholar]. In light of substantial cost and some risk associated with blood product use, we pursued a detailed study of red blood cell (RBC) and platelet (PLT) transfusion needs during an HCT course. Limited available data on the extent of blood product utilization after HCT include Osterwalder et al. [2Osterwalder B. Gratwohl A. Reusser P. Tichelli A. Speck B. Hematological support in patients undergoing allogenetic bone marrow transplantation.Recent Results Cancer Res. 1988; 108: 44-52Crossref PubMed Scopus (7) Google Scholar] reporting 39 HCT patients needing a range of 1 to 32 RBC and 1 to 11 PLT transfusions, and Pihlstedt et al. [3Pihlstedt P. Paulin T. Sundberg B. Nilsson B. Ringden O. Blood transfusion in marrow graft recipients.Ann Hematol. 1992; 65: 66-70Crossref PubMed Scopus (15) Google Scholar] describing 182 allogeneic transplants patients receiving 1 to 63 RBC and 2 to 394 PLT transfusions. We reviewed the blood product use in 229 consecutive patients at our institution and assessed factors associated with greater transfusion needs.Materials and MethodsPatients and MethodsUsing prospectively collected data from the University of Minnesota Blood and Marrow Transplant Database, we reviewed demographics and HCT complications in 229 consecutive adult patients who underwent allogeneic HCT. This was supplemented with complete and detailed transfusion data for the initial 3 months after HCT. We also detailed the preparative regimen, gender, race, and number of prior transplants to determine associated factors that may have altered their blood product utilization, RBC and PLT engraftment, and time to transfusion independence. The patients were divided into 4 groups based on the underlying disease: leukemia (n = 147), lymphoma/myeloma (n = 82), nonmalignant disorders (43), and Fanconi anemia (7). The formal analysis was limited to the more homogeneous subset of patients with either leukemia or lymphoma/myeloma (N = 229). The patients received a preparative regimen classified as either myeloablative (MA) plus filgrastim-mobilized sibling donor PBSC, reduced-intensity conditioning (RIC) plus sibling donor PBSC, UCB MA, or UCB RIC. Patients were given prophylaxis for graft-versus-host disease (GVHD) and supportive care based on the defined institutional guidelines and active investigational protocols.Transfusion Support and EndpointsProphylactic platelet transfusions were administered to nonbleeding patients at a pretransfusion trigger of <10,000/μL unless additional risks of bleeding (eg, mucositis, plasma coagulation disorder, sepsis) were present. Treatment for therapeutic bleeding followed WHO guidelines. Red blood cell transfusions were administered for Hb <8 g/dL. All products were irradiated in vitro with 25 Gy prior to transfusion.Transfusion independence was defined as the day of the last post-HCT PLT transfusion with no PLT transfusions in the following 7 days. RBC transfusion independence was defined as the day of the last RBC transfusion with no transfusion in the following 30 days. The total number of transfusion episodes and the total transfused PLT and RBC units during the transplant period were determined. Incidence and time to hematologic and RBC independence was determined for the total (N = 229) and separately for the leukemia (n = 147) and lymphoma/myeloma (n = 82) subgroups.Statistical AnalysisComparison of patients’ characteristics used the χ2 test or Fisher’s exact test for categoric variables, and Wilcoxon’s rank-sum test for continuous variables. The cumulative incidence of RBC and PLT independence was used by treating deaths from other causes as competing risks. Univariate analysis was performed for differences in PLT independence and RBC independence, whereas risk factor analysis of time to RBC transfusion independence and time to PLT transfusion independence was performed using competing risk regression analysis. Risk factors considered included: donor and graft source, conditioning regimen (myeloablative versus RIC), race, gender, and HCT number for those with a prior HCT. All P values reported were 2-sided and P values <.05 were considered statistically significant. Marginal mean was used to report on the monthly and total number of PLT and RBC units used. Marginal mean is defined as the weighted average of the conditional means, with weights equal to the probability of being in the subgroup determined by the corresponding value of the conditioning variable. Data analysis was performed using SAS software, version 8.0. The University of Minnesota institutional review board approved the data collection and analysis.ResultsPatient CharacteristicsWe studied 229 consecutive allogeneic adult HCT recipients with hematologic malignancies receiving either PBSC or UCB grafts (Table 1). Of these, 140 were males (61%), 196 were Caucasian (86%), 131 (57%) received UCB, and 98 (43%) PBSC grafts. One hundred eighteen (52%) received RIC and 111 (48%) MA conditioning. Thirty-nine (17%) had a previous (38 autologous; 1 allogeneic) HCT. In the entire group, hematopoietic reconstitution manifest as sustained neutrophil recovery was prompt (UCB median 17, range: 2-45 days, and PBSC median 14, range: 3-34 days).Table 1Patient Demographics and Graft SourceNPercentTotal229100%Graft source and conditioning intensity PBSC RIC4620% PBSC myeloablative5223% UCB RIC7231% UCB myeloablative5926%Sex Male/female140/8961%/39%Race White/other196/3186%/14%Transplant number 119083% >13917%Diagnosis Leukemia14764% Lymphoma/myeloma8236%PBSC indicates peripheral blood stem cell; RIC, reduced-intensity conditioning; UCB, umbilical cord blood. Open table in a new tab Transfusion IndependenceTime to transfusion independence by donor type and conditioning regimen subgroups is shown in Table 2. RBC independence occurred at a median of 44 (range: 7-141) days and PLT independence at a median of 33 (range: 11-172) days after HCT. Although median time to RBC independence did not differ based upon donor source or HCT number, it was somewhat longer after MA conditioning (median 55 [range: 9-141] days versus 42 [7-127] days, P = .43) and among women (56 days versus 42 days, P = .26). The time to PLT independence was prolonged in UCB recipients compared to PBSC, although it did not reach statistical significance (41 [range: 18-172] days versus 14 [11-161] days, P = .52) and in recipients of second HCT (48 days versus 32 days, P = .09). By 6 months after HCT, only 76 of 131 (58%) UCB recipients versus. 59 of 98 (60%) PBSC recipients were independent of RBC transfusions, and 92 of 131(70%) UCB and 65 of 98 (66%) PBSC were independent of PLT support.Table 2Time to RBC and Platelet Transfusion IndependenceRBC IndependencePlatelet IndependenceNRBC Independent by 6 months (n)Median time to independence (range, days)Platelet Independent by 6 months (n)Median time to independence (range, days)Total22913544 (7-141)15733 (11-172)Graft source UCB1317644.59241 PBSC9859446514Conditioning RIC1186841.58029 Myeloablative11167557735Transplant number >13917442148 119011844.513632RBC indicates red blood cells; PBSC, peripheral blood stem cells; UCB, umbilical cord blood. Open table in a new tab Transfusion Independence within Disease SubgroupsBecause either diagnosis or prior therapies confounded the assessment of transfusion needs, we analyzed the cumulative transfusion requirements of patients with leukemia and with myeloma/lymphoma separately. Of 147 patients with leukemia, 98 (67%) received UCB grafts, 90 (62%) received MA conditioning regimen, and 126 patients (86%) had no prior transplant. Eighty-three patients (56%) achieved RBC independence within 6 months of transplant with a median time to RBC independence of 49 (range: 11-160) days. Time to RBC independence was somewhat longer in females (63 versus 43 days, P = .27) and after MA conditioning (56 versus 43 days, P = .21) but did not reach statistical significance. Ninety-five patients (65%) achieved PLT independence by 6 months with a median time of 35 days. Time to PLT independence was longer yet not significant after UCB (43 versus 25 days, P = .43) and in recipients of second transplants (57 days versus 34 days, P = .16). However, within the leukemia group, we observed no statistically significant differences in the time to PLT transfusion independence based on donor source (Figure 1), conditioning regimen, race, gender, or number of transplants. Among the patients who received RIC conditioning, median times to RBC and PLT transfusion independence in the UCB subgroup were 41.5 and 39 days and were not different from the PBSC subgroup (58 and 12 days).Of 82 patients with lymphoma/myeloma, 32 (39%) had UCB grafts, 21 (26%) had MA conditioning, and 18 (22%) had received a prior transplant. Fifty-two patients (63%) achieved RBC independence by 6 months, with a median time to independence of 43 days. The median time to RBC independence was somewhat longer in females (52 versus 35 days, P = .27), recipients of UCB (40 versus 10 days, P = .10), those with prior HCT (54 versus 35 days, P = .02), and following MA conditioning (47 versus 41 days, P = .03). Sixty-two patients (75%) achieved PLT independence by 6 months, with a median time of 21 days. The time to PLT independence was longer yet not statistically significant in recipients of UCB versus PBSC (40 versus 10 days, P = .16) and also in those with a prior transplant (48 versus 15 days, P = .01). There were no differences in time to PLT independence based on conditioning regimen (21 days for myeloablative versus 20 days for RIC) or other clinical factors.Multivariate Regression Analysis of Transfusion IndependenceUsing competing risk regression analysis, we evaluated factors influencing the time to platelet or RBC independence in the different disease subgroups. In the lymphoma/myeloma group, there was a statistically significant longer time to RBC independence using myeloablative conditioning (P = .03) and following second HCTs (P = .02). Similarly, time to PLT independence was significantly longer after MA conditioning (P = .01) and second HCT (P = .009). There was no significant difference based on the graft source (UCB versus PBSC, P = .16). However, within the larger subgroup of patients with leukemia, no factors were independently associated with the time to achieve either RBC or PLT independence.Transfusion Requirements in Patients with LeukemiaPatients in the larger leukemia subgroup were further studied to detail the number of transfusions required during each of the first 3 months after HCT. The marginal mean number of RBC and PLT transfusions received in each month was compared in cohorts defined by the graft source (UCB versus PBSC) and conditioning regimen intensity (MA versus RIC) (Table 3).Table 3Marginal RBC and Platelet for values each time of the marginal mean of RBC and platelet transfusions for graft source and conditioning values each time of the marginal mean of RBC and platelet transfusions for graft source and conditioning source values each time of the marginal mean of RBC and platelet transfusions for graft source and conditioning intensity indicates confidence RIC, reduced-intensity conditioning; RBC indicates red blood cells; PBSC, peripheral blood stem cells; UCB, umbilical cord HCT, hematopoietic cell P values each time of the marginal mean of RBC and platelet transfusions for graft source and conditioning Open table in a new tab to PBSC, UCB recipients required a greater number of RBC transfusions during each of the first 3 months and statistical significance for months 2 and Patients who received MA conditioning also had a greater for PLT transfusions (Table Similarly, during each of the first 3 months UCB recipients required significantly more PLT transfusions PBSC (P < .01). The marginal mean and total number of PLT and RBC transfusions were significantly in UCB recipients during the first 3 months post-HCT (Figure MA conditioning was associated with significantly increased PLT requirements during month and a in months 2 and but RBC requirements were in conditioning mean of platelet and RBC transfusion are the marginal of cumulative PLT and RBC transfusions the first 6 months post-HCT for patients with UCB recipients have significantly greater mean PLT (P < .01) and RBC (P = transfusion needs compared to of HCT have substantial transfusion in the with either delayed recovery of to or Even using for blood product as RBC for Hb <8 or PLT for a transfusion needs The the of PLT transfusions by that bleeding episodes are and not associated with PLT in the et al. of platelet transfusions and of Scholar]. The of allogeneic HCT recipients are to infections or have risks of bleeding of mucositis, plasma coagulation or complications that a for a PLT trigger for We our detailed analysis of total blood product and time to transfusion independence in allogeneic HCT patients with leukemia are transfused and prior to guidelines in HCT patients are from other subgroups of as data from HCT are less well defined B. A. Ringden O. of a platelet transfusion trigger of 10 versus 30 in allogeneic hematopoietic cell transplant PubMed Scopus Google et associated with to platelet transfusion following hematopoietic stem cell Marrow Google et and of hematopoietic stem cell transplant patients significant using platelet transfusion of 10 or 20 PubMed Scopus Google bleeding complications in patients after hematopoietic stem cell transplantation with platelet transfusion of 10 and 20 PubMed Scopus Google Scholar]. The for PLT transfusion in HCT recipients has with guidelines as an for prophylaxis The platelet and in patients with PubMed Scopus Google Scholar]. that a platelet of less used in leukemia and HCT recipients P. et for platelet transfusions in with PubMed Scopus Google et and cost of a 10 trigger for platelet transfusions compared with the 20 a in patients with Google A. to in and of the platelet transfusion PubMed Scopus Google Scholar]. In some the transfusion from to in marrow transplant recipients did not increase bleeding or of but PLT use by A. et of a on platelet analysis in bone marrow transplant patients from a Marrow Google Scholar]. The of is used by to PLT transfusions B. A. Ringden O. of a platelet transfusion trigger of 10 versus 30 in allogeneic hematopoietic cell transplant PubMed Scopus Google bleeding complications in patients after hematopoietic stem cell transplantation with platelet transfusion of 10 and 20 PubMed Scopus Google et of platelet transfusion and bleeding incidence in hematopoietic stem cell transplant versus Blood Marrow Full Text Full Text PDF PubMed Scopus Google for RBC transfusion in HCT has in This could to the use of less intensive and factor into the transplant or bleeding episodes to prolonged bleeding complications in patients after bone marrow Hematol. PubMed Scopus Google Scholar]. transfusion trigger of Hb <8 is used at our and although are for patients with A. review of transfusion and after hematopoietic cell PubMed Scopus Google Scholar]. have also been for transplant recipients with delayed engraftment, and malignancies [3Pihlstedt P. Paulin T. Sundberg B. Nilsson B. Ringden O. Blood transfusion in marrow graft recipients.Ann Hematol. 1992; 65: 66-70Crossref PubMed Scopus (15) Google has been more used in of the risk of associated and the on a more for et total and followed by hematopoietic cell transplantation (HCT) from or unrelated and with and complete and sustained in patients with Scopus Google Scholar]. et al. et al. Platelet recovery and transfusion needs after intensity conditioning allogeneic peripheral blood stem cell Hematol. Scholar] reported data on PLT recovery and transfusion needs in adult allogeneic sibling donor HCT recipients with RIC. PLT recovery was at a median of days with of the patients a PLT by day PLT prior to conditioning and the of significantly day PLT recovery and PLT transfusion Similarly, the median time to PLT independence in our RIC is 14 days, with receiving UCB grafts, may engraftment compared to other donor sources et to engraftment after myeloablative umbilical cord blood transplantation with Marrow 2009; PubMed Scopus Google Scholar]. unrelated donor sources and MA conditioning are also associated with delayed PLT time to more PLT recovery in UCB HCT has been reported to as as day and the was to the graft cell post-HCT and the of P. A. et among recipients of transplants from unrelated PubMed Scopus Google Scholar]. Although the incidence of PLT transfusion independence at 6 months did not we observed that UCB grafts to delayed PLT independence compared to other donor sources et transplantation of and umbilical cord blood from unrelated analysis of engraftment and graft-versus-host Google Scholar] and an greater transfusion engraftment, a to PLT recovery in UCB has been associated with a cell and A. et of in the graft-versus-host on engraftment in adult patients receiving reduced-intensity cord blood 2009; PubMed Scopus Google also observed less frequent and transfusion independence in recipients a prior HCT. In our of 39 HCT could of the graft source, prior marrow from prior or their leukemia although we could not the of delayed PLT recovery in In et al. et associated with in allogeneic hematopoietic cell transplantation with conditioning after myeloablative hematopoietic cell PubMed Scopus Google Scholar] reported on 147 patients receiving a regimen followed by either (n = or unrelated (n = allogeneic RIC HCT of disease after a prior or allogeneic transplant who only a median of and 4 for PLT and RBC transfusions, et al. et after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have a prior Marrow PubMed Scopus Google Scholar] reported a median of 11 days to a PLT of in a of sibling donor RIC HCT recipients who had after a prior transfusion needs in the first 60 days after allogeneic HCT were observed at a median of 4 RBC units for RIC and 12 units for MA conditioning et after intensity conditioning allogeneic stem cell value of prior Hb PubMed Scopus Google more in patients with leukemia units for RIC and units for report of only 2 RBC units after RIC T. transfusion requirements for patients receiving compared with peripheral blood stem cell transplants from PubMed Scopus Google Scholar]. Factors associated with increased RBC transfusion requirements include and [3Pihlstedt P. Paulin T. Sundberg B. Nilsson B. Ringden O. Blood transfusion in marrow graft recipients.Ann Hematol. 1992; 65: 66-70Crossref PubMed Scopus (15) Google Scholar]. data that MA conditioning and UCB grafts are associated with transfusion analyzed the increased cost for UCB compared to or unrelated donor HCT with to of the costs in different HCT attributable to transfusion product needs of hematopoietic cell of umbilical cord blood and donor transplantation and the of Blood Marrow 2009; Full Text Full Text PDF PubMed Scopus Google Scholar]. data that patients receiving UCB grafts required a mean of 15 PLT transfusions and 4 RBC transfusions during the first 3 months on costs from the for and report on blood transfusion irradiated RBC PLT irradiated the increase in transfusion requirements with UCB grafts transfusion-associated costs by during the first 3 months to plus additional costs for and the for transfusion and that RBC and PLT transfusion requirements are somewhat increased with UCB grafts, although are by RIC HCT. The use of UCB as a donor source may transfusion independence and increase the costs of HCT as to transfusion and hematopoietic recovery may limit the transfusion and the costs of prolonged RBC and PLT transfusions. IntroductionOver the past decade, there has been an increase in the use of allogeneic hematopoietic stem cell transplants (HCT) to treat hematologic malignancies and life-threatening nonmalignant hematologic disorders. This increase is attributable to newer techniques, safer preparative regimens, and expanded use of peripheral blood stems cells (PBSC) and umbilical cord blood (UCB) as graft sources [1Hiemenz J.W. Management of infections complicating allogeneic hematopoietic stem cell transplantation.Semin Hematol. 2009; 46: 289-312Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar]. Even using newer, less intensive regimens, patients undergoing HCT will receive frequent blood products as part of their supportive therapy [2Osterwalder B. Gratwohl A. Reusser P. Tichelli A. Speck B. Hematological support in patients undergoing allogenetic bone marrow transplantation.Recent Results Cancer Res. 1988; 108: 44-52Crossref PubMed Scopus (7) Google Scholar]. In light of substantial cost and some risk associated with blood product use, we pursued a detailed study of red blood cell (RBC) and platelet (PLT) transfusion needs during an HCT course. Limited available data on the extent of blood product utilization after HCT include Osterwalder et al. [2Osterwalder B. Gratwohl A. Reusser P. Tichelli A. Speck B. Hematological support in patients undergoing allogenetic bone marrow transplantation.Recent Results Cancer Res. 1988; 108: 44-52Crossref PubMed Scopus (7) Google Scholar] reporting 39 HCT patients needing a range of 1 to 32 RBC and 1 to 11 PLT transfusions, and Pihlstedt et al. [3Pihlstedt P. Paulin T. Sundberg B. Nilsson B. Ringden O. Blood transfusion in marrow graft recipients.Ann Hematol. 1992; 65: 66-70Crossref PubMed Scopus (15) Google Scholar] describing 182 allogeneic transplants patients receiving 1 to 63 RBC and 2 to 394 PLT transfusions. We reviewed the blood product use in 229 consecutive patients at our institution and assessed factors associated with greater transfusion

References

23